LEADER 05156nam 2201369z- 450 001 9910367745903321 005 20210211 010 $a3-03921-707-0 035 $a(CKB)4100000010106258 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/51774 035 $a(oapen)doab51774 035 $a(EXLCZ)994100000010106258 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aLinks between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 online resource (348 p.) 311 08$a3-03921-706-2 330 $aTissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs. 517 $aLinks between Fibrogenesis and Cancer 606 $aMedicine$2bicssc 610 $aacute lung injury 610 $aanaplastic lymphoma kinase 610 $aangiogenesis 610 $aantitumor efficacy 610 $aapoptosis 610 $ableomycin 610 $abreast cancer 610 $abutylidenephthalide 610 $acancer 610 $acancer-associated fibroblasts 610 $acancer-associated fibroblasts (CAFs) 610 $acarcinogenesis 610 $acirrhosis 610 $aclinical symptoms 610 $acommon pathways 610 $acrizotinib 610 $acystic formation 610 $acytokine 610 $acytokines 610 $aDHA 610 $adiagnosis 610 $aEMT 610 $aErk1/2 610 $aextracellular matrix 610 $afibrosis 610 $agenetic instability 610 $aGPR120 610 $aGPR40 610 $agrowth factor 610 $aHBV 610 $aHCV 610 $ahepatic stellate cells 610 $ahepatic stellate cells (HSCs) 610 $ahepatocellular carcinoma 610 $ahepatocellular carcinoma (HCC) 610 $ahepatocytes 610 $aheterogeneity 610 $aHippo pathway 610 $aidiopathic pulmonary fibrosis 610 $aidiopathic pulmonary fibrosis (IPF) 610 $aimmunohistochemistry 610 $ainflammation 610 $ainterstitial fluid pressure 610 $aleiomyoma 610 $aleiomyosarcoma 610 $alipopolysaccharide 610 $alncRNA 610 $alung cancer 610 $alung cancer (LC) 610 $amarker 610 $amechanotransduction 610 $ametabolic reprogramming 610 $ametastasis 610 $amiRNA 610 $amyometrium 610 $an/a 610 $ananoparticles 610 $anon-alcoholic steatohepatitis 610 $anon-small cell lung cancer (NSCLC) 610 $aomega-3 fatty acid 610 $apathogenesis 610 $apathology 610 $apathophysiology 610 $aprotein S 610 $apulmonary fibrosis 610 $areactive oxygen species 610 $aregeneration 610 $arenal injury 610 $asignal pathway 610 $aSMAD 610 $asmooth muscle tumor of uncertain malignant potential 610 $aSOX2 610 $aSREBP-1 610 $atargeted therapy 610 $aTAZ 610 $aTGF-? 610 $atherapy 610 $atransforming growth factor-? 610 $atumor 610 $atumor microenvironment 610 $atumor necrosis factor ? 610 $atumor stiffness 610 $atype I collagen 610 $auterine fibroid 610 $aWnt 610 $aYAP 615 7$aMedicine 700 $aGabazza$b Esteban C$4auth$01288168 906 $aBOOK 912 $a9910367745903321 996 $aLinks between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges$93020666 997 $aUNINA